Updated time: 2021-10-22 12:14:26
06A-1001102
TW I449791
The invention provides a method for predicting the response of/ predicting prognosis in an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) In the methods of the invention, clustered genomic alterations in specific chromosomes (in particular chromosomes 5p, 7p, 8q or 14q) are determined as a tool for predicting the response or prognosis.
Since the molecular basis of the response heterogeneity is still unknown, no biomarker is available for predicting responsiveness of a lung adenocarcinoma subject receiving EGFR treatment.
Predicting the response and prognosis of an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
SUNG-LIANG YU, SHIN-SHENG YUAN, GEE-CHEN CHANG, HSUAN-YU CHEN, KER-CHAU LI, PAN-CHYR YANG
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

METHOD FOR PREDICTING RESPONSE OR PROGNOSIS OF LUNG ADENOCARCINOMA WITH EGFR-ACTIVATING MUTATIONS